Claus Bachert
YOU?
Author Swipe
View article: Distinct Effects of Biological Treatments on Eosinophils and Neutrophils in Chronic Rhinosinusitis With Nasal Polyp Patients
Distinct Effects of Biological Treatments on Eosinophils and Neutrophils in Chronic Rhinosinusitis With Nasal Polyp Patients Open
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is generally characterized by tissue‐infiltrating eosinophils. Various biologic treatments, targeting the inflammation, have demonstrated efficacy in reducing nasal polyp size an…
View article: Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial
Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial Open
Background Subcutaneous allergen immunotherapy (SCIT) has a longstanding history as a safe and effective treatment. Nevertheless, to meet the European Medicines Agency's regulatory requirements for continued market authorization, its effic…
View article: TLR4+group 2 innate lymphoid cells contribute to persistent type 2 immunity in airway diseases
TLR4+group 2 innate lymphoid cells contribute to persistent type 2 immunity in airway diseases Open
Group 2 innate lymphoid cells (ILC2s) directly contribute to local inflammation in type 2 inflammatory airway diseases. Here, we identify ILC2 subsets by single cell RNA sequencing in chronic rhinosinusitis with nasal polyps (CRSwNP) and i…
View article: Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study
Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study Open
The OverSEA study is the largest European initiative providing recommendations for optimizing the management of patients with SEA and comorbid CRSwNP. It underscores the importance of evaluating patients with SEA for comorbid upper airways…
View article: Amphiregulin Mediates Epithelial Cell–Eosinophil Interactions and Amplifies Inflammation in Chronic Rhinosinusitis With Nasal Polyps
Amphiregulin Mediates Epithelial Cell–Eosinophil Interactions and Amplifies Inflammation in Chronic Rhinosinusitis With Nasal Polyps Open
Background Eosinophils easily accumulate in the intra‐epithelial layer and subepithelial regions in eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP). While several factors influence the migration of eosinophils from peripher…
View article: The alphaherpesvirus gE/gI glycoprotein complex and proteases jointly orchestrate invasion across the host’s upper respiratory epithelial barrier
The alphaherpesvirus gE/gI glycoprotein complex and proteases jointly orchestrate invasion across the host’s upper respiratory epithelial barrier Open
Alphaherpesviruses, including herpes simplex virus type 1 (HSV-1), pseudorabies virus (PRV), and bovine herpesvirus type 1 (BoHV-1), are significant pathogens affecting humans and animals. These viruses penetrate the upper respiratory trac…
View article: Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab
Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab Open
ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52).
View article: Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison Open
Dupilumab was associated with greater improvements in CRSwNP-related outcomes versus mepolizumab.
View article: The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA
The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA Open
Background: The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact…
View article: The Belgian IgE study: Staphylococcus aureus toxins in adult severe asthma
The Belgian IgE study: Staphylococcus aureus toxins in adult severe asthma Open
peer reviewed
View article: Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP
Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP Open
Most patients with CRSwNP achieve clinically meaningful responses to dupilumab by week 16, and most such patients in our study had maintenance and durability of response with continued treatment over time.
View article: Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia
Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia Open
Background: This randomised, double-blind, placebo-controlled, parallel-group, 52-week Phase III study (MERIT; NCT04607005) assessed mepolizumab efficacy and safety in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)/eosinop…
View article: Dupilumab improved objective and patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and complete nasal obstruction
Dupilumab improved objective and patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and complete nasal obstruction Open
Aim: The impact of complete bilateral nasal obstruction [nasal polyp score (NPS) = 8/8] on treatment outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) is unclear. This post hoc analysis assessed disease burden and dupilumab eff…
View article: Dupilumab efficacy across serum <scp>IgE</scp> and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
Dupilumab efficacy across serum <span>IgE</span> and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis Open
The pathophysiology of chronic rhinosinusitis with nasal polyposis (CRSwNP) is driven primarily by interleukin (IL)-4, IL-13, and IL-5 cytokines, and up to 87% of CRSwNP patients have a type 2 (T2) inflammatory signature.1, 2 Blood eosinop…
View article: Human CD127 negative ILC2s show immunological memory
Human CD127 negative ILC2s show immunological memory Open
ILC2s are key players in type 2 immunity and contribute to maintaining homeostasis. ILC2s are also implicated in the development of type 2 inflammation–mediated chronic disorders like asthma. While memory ILC2s have been identified in mous…
View article: Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial
Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial Open
Aims Benralizumab, a humanized, afucosylated monoclonal antibody against the interleukin 5 receptor, α subunit, causes rapid depletion of eosinophils by antibody‐dependent cellular cytotoxicity. We investigated the pharmacokinetic and phar…
View article: The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps Open
Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly a type 2 inflammatory disease associated with type 2 (T2) cell responses and epithelial barrier, mucociliary, and olfactory dysfunction. The inflammatory cytokines interleu…
View article: Evaluation of ongoing mepolizumab treatment in chronic rhinosinusitis with nasal polyps
Evaluation of ongoing mepolizumab treatment in chronic rhinosinusitis with nasal polyps Open
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and paranasal sinuses. Eosinophilic inflammation is described as a common endotype. The anti-interleukin-5 (IL-5…
View article: Associations of tenascin C with Th2 response, edema degree, and disease severity in patients with chronic rhinosinusitis with nasal polyps
Associations of tenascin C with Th2 response, edema degree, and disease severity in patients with chronic rhinosinusitis with nasal polyps Open
The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information sup…
View article: Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy? Open
Understanding the immunological basis of CRSwNP opens up new non-surgical therapeutic approaches with biologics for patients with severe, uncontrolled courses. Here, we provide recommendations for follow-up, adherence to therapy intervals,…
View article: Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the <scp>SINUS</scp>‐52 trial
Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the <span>SINUS</span>‐52 trial Open
Objectives This post hoc analysis assessed disease characteristics and response to dupilumab treatment in male and female patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (SINUS‐52 study; NCT02898454). Methods Patient…
View article: Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma
Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma Open
Dupilumab significantly reduced the requirement for SCS and improved asthma outcomes irrespective of history of asthma exacerbation or prior SCS use vs placebo in patients with CRSwNP and coexisting asthma, demonstrating concomitant reduct…
View article: Human CD127 negative ILC2s show immunological memory
Human CD127 negative ILC2s show immunological memory Open
SUMMARY Group 2 Innate Lymphoid Cells (ILC2s) serve as key players in type 2 immunity and contribute significantly to maintaining homeostasis and responding to inflammation. Notably, ILC2s are closely implicated in the development of aller…